← Back to Clinical Trials
Recruiting NCT07523893

NCT07523893 Comparative Effects of Shockwave Therapy and Eccentric Exercises in Patients With Lateral Epicondylitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07523893
Status Recruiting
Phase
Sponsor Ibadat International University, Islamabad
Condition Tennis Elbow
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-02-02
Primary Completion 2026-06-16

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Shockwave TherapyEccentric exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-02-02 with a primary completion date of 2026-06-16.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this randomized controlled trial is to compare the effects of shockwave therapy and eccentric exercises on pain, functional ability, quality of life, grip strength and range of motion in patients with lateral epicondylitis. Participants will be randomly assigned to either Group A (Shockwave therapy) or Group B (Eccentric Exercises) using a computer-generated random number tables method. The intervention will be provided over five weeks, with three sessions per week (total of 15 sessions): Group A (Shockwave therapy): Participants will receive shockwave therapy, for 5 min with energy level 7.0 m J and frequency 6 Hz. Group B (Eccentric Exercises): Participants will receive eccentric exercises, repeating each 10 repetitions 3 sets per session with a 1 min rest between each of them. Outcomes will be assessed at baseline, week 0 and week 5 to evaluate which exercise program is more effective in reducing symptoms and improving functional outcomes.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with Lateral epicondylitis * Patients with 20-50 years * Both males and females * Willing to participate and provide informed consent Exclusion Criteria: * Patients with recent trauma (fractures, injury etc.) * Patients with blood clotting disorder (including thrombosis), oral anti-coagulants, and pacemaker, tumors at site of treatment, infected area or skin rupture or abrasion at the site of treatment, pregnancy. * Cervical Radiculopathy or any diseases that mimic or refer pain to elbow. * Patients who received steroid injection within 6 weeks.

Contact & Investigator

Central Contact

Yousra Bahadar, MS-PT(MSK)*

✉ yousrabahadar111@gmail.com

📞 00923130522747

Principal Investigator

Muhammad Nazim Farooq, PhD-PT

PRINCIPAL INVESTIGATOR

Ibadat International University

Frequently Asked Questions

Who can join the NCT07523893 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Tennis Elbow. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07523893 currently recruiting?

Yes, NCT07523893 is actively recruiting participants. Contact the research team at yousrabahadar111@gmail.com for enrollment information.

Where is the NCT07523893 trial being conducted?

This trial is being conducted at Islamabad, Pakistan.

Who is sponsoring the NCT07523893 clinical trial?

NCT07523893 is sponsored by Ibadat International University, Islamabad. The principal investigator is Muhammad Nazim Farooq, PhD-PT at Ibadat International University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology